Transgenic mice expressing human Bcl-2 in their neurons are resistant to 6-hydroxydopamine and 1-methyl-4-phenyl-1,2,3,6- tetrahydropyridine neurotoxicity
Open accessThe DOI matches its Crossref record; 4 of the 4 references it cites were found in a registry or an index.
Abstract
The protooncogene bcl-2 inhibits neuronal apoptosis during normal brain development as well as that induced by cytotoxic drugs or growth factor deprivation. We have previously demonstrated that neurons of mice deficient in Bcl-2 are more susceptible to neurotoxins and that the dopamine (DA) level in the striatum after systemic 1-methyl-4-phenyl-1,2,3,6 tetrahydropyridine (MPTP) administration was significantly lower than in wild-type mice. In the present study we have used transgenic mice overexpressing human Bcl-2 under the control of neuron-specific enolase promoter (NSE- hbcl -2) to test the effects of the neurotoxins 6-hydroxydopamine (6-OHDA) and MPTP on neuronal survival in these mice. Primary cultures of neocortical neurons from normal and transgenic mice were exposed to these dopaminergic neurotoxins. Addition of 6-OHDA resulted in cell death of essentially all neurons from normal mice. In contrast, in cultures generated from heterozygous NSE- hbcl-2 transgenic mice, only 69% of the cells died while those generated from homozygous transgenic mice were highly resistant and exhibited only 34% cell death. A similar effect was observed with neurons treated with MPP + . Moreover, while the striatal dopamine level after MPTP injections was reduced by 32% in the wild type, the concentration remained unchanged in the NSE- hbcl-2 heterozygous mice. In contrast levels of glutathione-related enzymes were unchanged. In conclusion, overexpression of Bcl-2 in the neurons provided protection, in a dose-dependent manner, against neurotoxins known to selectively damage dopaminergic neurons. This study provides ideas for inhibition of neuronal cell death in neurodegenerative diseases and for the development of efficient neuroprotective gene therapy.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The proto-oncogene Bcl-2 and its role in regulating apoptosis
Kroemer, G. (1997) · Nature Medicine · doi:10.1038/nm0697-614 · Cited by 1,739
Immunohistochemical detection of 4-hydroxynonenal protein adducts in Parkinson disease.
Yoritaka, A., Hattori, N., Uchida, K., Tanaka, M., Stadtman, E. R., & Mizuno, Y. (1996) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.93.7.2696 · Cited by 981
The oxidant stress hypothesis in Parkinson's disease: Evidence supporting it
Fahn, S., & Cohen, G. (1992) · Annals of Neurology · doi:10.1002/ana.410320616 · Cited by 927
Burns, R. S., LeWitt, P. A., Ebert, M. H., Pakkenberg, H., & Kopin, I. J. (1985) · New England Journal of Medicine · doi:10.1056/nejm198505303122203 · Cited by 244
Cited by
Dauer, W., & Przedborski, S. (2003) · Neuron · doi:10.1016/s0896-6273(03)00568-3 · Cited by 5,469
Blum, D., Torch, S., Lambeng, N., Nissou, M.-F., Benabid, A.-L., Sadoul, R., & Verna, J.-M. (2001) · Progress in Neurobiology · doi:10.1016/s0301-0082(01)00003-x · Cited by 1,246
Role of reactive oxygen species in apoptosis: implications for cancer therapy
Matés, J. M., & Sánchez-Jiménez, F. M. (2000) · The International Journal of Biochemistry & Cell Biology · doi:10.1016/s1357-2725(99)00088-6 · Cited by 771
Experimental models of Parkinson's disease
Beal, M. F. (2001) · Nature Reviews Neuroscience · doi:10.1038/35072550 · Cited by 637
Targeting programmed cell death in neurodegenerative diseases
Vila, M., & Przedborski, S. (2003) · Nature Reviews Neuroscience · doi:10.1038/nrn1100 · Cited by 546
Antioxidant enzymes and their implications in pathophysiologic processes
Mates, J. M. (1999) · Frontiers in Bioscience · doi:10.2741/a432 · Cited by 520
The BCL2 family: from apoptosis mechanisms to new advances in targeted therapy
Vogler, M., Braun, Y., Smith, V. M., Westhoff, M.-A., Pereira, R. S., Pieper, N. M., Anders, M., Callens, M., Vervliet, T., Abbas, M., et al. (2025) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-025-02176-0 · Cited by 462
Pesah, Y., Pham, T., Burgess, H., Middlebrooks, B., Verstreken, P., Zhou, Y., Harding, M., Bellen, H., & Mardon, G. (2004) · Development · doi:10.1242/dev.01095 · Cited by 443
Langston, J. W. (2017) · Journal of Parkinson’s Disease · doi:10.3233/jpd-179006 · Cited by 424
Oxidative stress and regulated cell death in Parkinson’s disease
Dionísio, P. A., Amaral, J. D., & Rodrigues, C. M. P. (2021) · Ageing Research Reviews · doi:10.1016/j.arr.2021.101263 · Cited by 424
Vila, M., Jackson-Lewis, V., Vukosavic, S., Djaldetti, R., Liberatore, G., Offen, D., Korsmeyer, S. J., & Przedborski, S. (2001) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.051633998 · Cited by 372
Self-citationOxidative stress in apoptosis and cancer: an update
Matés, J. M., Segura, J. A., Alonso, F. J., & Márquez, J. (2012) · Archives of Toxicology · doi:10.1007/s00204-012-0906-3 · Cited by 341
Improving the Survival of Grafted Dopaminergic Neurons: A Review over Current Approaches
Brundin, P., Karlsson, J., Emgård, M., Schierle, G. S. K., Hansson, O., Petersén, Å., & Castilho, R. F. (2000) · Cell Transplantation · doi:10.1177/096368970000900205 · Cited by 331
Viswanath, V., Wu, Y., Boonplueang, R., Chen, S., Stevenson, F. F., Yantiri, F., Yang, L., Beal, M. F., & Andersen, J. K. (2001) · The Journal of Neuroscience · doi:10.1523/jneurosci.21-24-09519.2001 · Cited by 315
BIOLOGICAL FUNCTIONALITY OF ELLAGIC ACID: A REVIEW
VATTEM, D. A., & SHETTY, K. (2005) · Journal of Food Biochemistry · doi:10.1111/j.1745-4514.2005.00031.x · Cited by 313
Lee, J.-M., Shih, A. Y., Murphy, T. H., & Johnson, J. A. (2003) · Journal of Biological Chemistry · doi:10.1074/jbc.m305204200 · Cited by 308
Mitochondrial Biology and Parkinson's Disease
Perier, C., & Vila, M. (2012) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a009332 · Cited by 306
Neuroprotective strategies for basal ganglia degeneration: Parkinson's and Huntington's diseases
Alexi, T. (2000) · Progress in Neurobiology · doi:10.1016/s0301-0082(99)00032-5 · Cited by 295
Zhao, H., Yenari, M. A., Cheng, D., Sapolsky, R. M., & Steinberg, G. K. (2003) · Journal of Neurochemistry · doi:10.1046/j.1471-4159.2003.01756.x · Cited by 289
PRZEDBORSKI, S., & VILA, M. (2003) · Annals of the New York Academy of Sciences · doi:10.1111/j.1749-6632.2003.tb07476.x · Cited by 283
Integrating Pathways of Parkinson's Disease in a Molecular Interaction Map
Fujita, K. A., Ostaszewski, M., Matsuoka, Y., Ghosh, S., Glaab, E., Trefois, C., Crespo, I., Perumal, T. M., Jurkowski, W., Antony, P. M. A., et al. (2014) · Molecular Neurobiology · doi:10.1007/s12035-013-8489-4 · Cited by 273
Cytoplasmic Pink1 activity protects neurons from dopaminergic neurotoxin MPTP
Haque, M. E., Thomas, K. J., D'Souza, C., Callaghan, S., Kitada, T., Slack, R. S., Fraser, P., Cookson, M. R., Tandon, A., & Park, D. S. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0705363105 · Cited by 263
Schimmer, A. D., O'Brien, S., Kantarjian, H., Brandwein, J., Cheson, B. D., Minden, M. D., Yee, K., Ravandi, F., Giles, F., Schuh, A., et al. (2008) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-08-0999 · Cited by 192
“Of note, 2 other AML patients with an 11q23 translocation [one of whom also had a newly acquired del(14) and a patient with ALL and mixed lineage leukemia (MLL) t(9;11)] were treated on this study but did not respond to obatoclax mesylate.”
BackgroundGhrelin antagonizes MPTP-induced neurotoxicity to the dopaminergic neurons in mouse substantia nigra
Jiang, H., Li, L.-J., Wang, J., & Xie, J.-X. (2008) · Experimental Neurology · doi:10.1016/j.expneurol.2008.05.006 · Cited by 144
BAX channel activity mediates lysosomal disruption linked to Parkinson disease
Bové, J., Martínez-Vicente, M., Dehay, B., Perier, C., Recasens, A., Bombrun, A., Antonsson, B., & Vila, M. (2014) · Autophagy · doi:10.4161/auto.28286 · Cited by 89
“In any event, the relationship between LMP and MOMP has proven complex and dependent on the pathological situation.(32,33) In some cellular settings, LMP precedes and contributes to the activation of mitochondria-dependent apoptosis(25) whereas in other situations LMP occurs downstream of mitochondrial permeabilizatio…”
BackgroundPeng, J., Xie, L., Stevenson, F. F., Melov, S., Di Monte, D. A., & Andersen, J. K. (2006) · The Journal of Neuroscience · doi:10.1523/jneurosci.3447-06.2006 · Cited by 53
Sampath, U., & Janardhanam, V. A. (2013) · Translational Neurodegeneration · doi:10.1186/2047-9158-2-23 · Cited by 19
Retracted
Metadata
- Authors
- Offen, D., Beart, P. M., Cheung, N. S., Pascoe, C. J., Hochman, A., Gorodin, S., Melamed, E., Bernard, R., & Bernard, O.
- Venue
- Proceedings of the National Academy of Sciences
- Published
- 1998-05-12
- Volume
- 95
- Issue
- 10
- Pages
- 5789-5794
- ISSN
- 0027-8424 (ISSN-L)
- 1091-6490
- OpenAlex
- W2037233527
- Cited by
- 232
- References
- 4
- FWCI
- 14.91
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.